Studies using bladder cancer tissue specimens have demonstrated that elevated or reduced expression of estrogen and progesterone receptors as well as alterations of their upstream or downstream pathways are associated with clinical outcomes [14, 15]. The gene discussed is PGR; the disease is urinary bladder cancer.